Exhibit 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
Pursuant to the requirement set forth in Rule 13a -14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:
1. | TheCompany’s Quarterly Report on Form 10-Q for the period ended September 30, 2013 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
2. | The information contained in thePeriodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 7, 2013 | By: |
| /s/ Andrew Gengos |
| |
|
|
| Name: | Andrew Gengos | |
|
|
| Title: | President and Chief Executive Officer | |
